CSIMarket
 
Tauriga Sciences Inc   (TAUG)
Other Ticker:  
 
 
Price: $0.0001 $0.00 0.000%
Day's High: $0.0001 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 317 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 297
 Employees 2
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Tauriga Sciences Inc

The Company entered into an exclusive memorandum of understanding with Immunovative Clinical Research, Inc. (“ICRI”), a Nevada corporation and wholly-owned subsidiary of Immunovative Therapies, Ltd. (“ITL”), an Israeli corporation pursuant to which the Company and ICRI intended to pursue a merger resulting in Novo owning ICRI.

Green Innovations

On May 31, 2013, the Company signed an exclusive North American license agreement with Green Innovations, Inc. (“Green Innovations”) for the commercialization of Bamboo-Based “100% Tree Free” products including hospital grade biodegradable disinfectant wipes. This 5-year license agreement functioned such that profits were to be split equally between Tauriga and Green Innovations.

Bacterial Robotics

On October 29, 2013, the Company entered into a strategic alliance with Bacterial Robotics, LLC (“Bacterial Robotics”). Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one or more specific functions, one such GMO being adopted to clean polluting molecules from nuclear waste, such GMO being referred herein as the existing BactoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10-year license agreement.

Pilus Energy

On November 25, 2013, the Company entered a definitive agreement to acquire Cincinnati, Ohio based Pilus Energy LLC (“Pilus Energy”), a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater. Upon consummation of the proposed transaction, which has been unanimously ratified by Tauriga’s board of directors, Pilus Energy will become a wholly-owned subsidiary of Tauriga. In addition, certain advisors of Pilus Energy will be incorporated into the existing management team of Tauriga and report directly to the Company’s Chief Executive Officer. A total of $100,000 was paid by Tauriga to Bacterial Robotics in connection with the execution of this November 2013 definitive agreement for the acquisition of Pilus Energy.



   Company Address: 4 Nancy Court Wappingers Falls 12590 NY
   Company Phone Number: 796-9926   Stock Exchange / Ticker: TAUG
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Chromadex Corporation

Legal Cannabis Company Surpasses Expectations in Fourth Quarter Earnings

CDXC, also known as ChromaDex Corporation, recently achieved a break-even point with a moderate increase in revenue. In the most recent fiscal period, their revenue rose by 0.953% to $21.20 million compared to the corresponding quarter a year prior. While this may seem positive, it is crucial to understand how CDXC performed in relation to its competitors in the legal cannabis industry. Unfortunately, CDXC underperformed in comparison to its contemporaries, who reported a business advance of 4.20% from the same quarter a year ago.
The previous quarter showed some improvement for CDXC, as their revenue increased by 8.725% from $19.50 million. Additionally, they achieved earnings of $0.114 million in the most recent fiscal period, a significant improvement compared to a net shortfall of $-1.418 million in the same quarter a year ago. Despite these positive aspects, CDXC's stockpiles have increased to $14.5 million, lower than the previous year's level of $14.7 million. Additionally, their accounts receivable has declined to $5.2 million, potentially indicating slowing demand.

Usana Health Sciences Inc

Usana Health Sciences Inc Sees Profits Surge Despite Revenue Dip

Despite a slight decrease in revenue during the October to December 2023 period, Usana Health Sciences Inc (USNA) managed to raise its earnings per share (EPS), showing significant growth in profit. The company reported a surge of 30.06% in profit per share to $0.87, while revenue fell by -2.722% to $221.76 million year on year.
Comparing these results with the prior financial reporting period, Usana Health Sciences Inc demonstrated impressive growth. EPS soared from $0.59 per share, and revenue advanced by 4.195% from $212.84 million. This shows that the company is continuing to increase its profitability, even in the face of slightly lower revenue.
Furthermore, Usana Health Sciences Inc highlighted its improving profit margins, with net margin rising to 7.56% and operating margin edging up to 10.92% during the October to December 2023 period. These figures indicate the company's ability to control costs and maximize its profitability.

Alterola Biotech Inc

Operating Losses Surge for Alterola Biotech Inc in Q4 2023 Financial Report

Alterola Biotech Inc, a legal cannabis company, has recently released its financial report for the October to December 2023 reporting cycle. The shareholders have not anticipated any changes in revenue during this period. However, they have expressed concerns over the company's operating loss, which amounted to $-1.108947 million.
To better understand the current state of the company, it is important to compare its performance with previous quarters. In the third quarter of 2023, Alterola Biotech Inc reported an operating loss of $0.540621 million. This indicates a significant increase in losses during the October to December 2023 reporting cycle.

Natural Alternatives International Inc

Natural Alternatives International Inc. Struggles with Serious Deterioration in Revenue during Second Quarter of 2024 Earnings Season

The financial results of Natural Alternatives International Inc. for the second quarter of 2024 paint a challenging picture for the company. The significant deficit per share, declining revenue, and net loss compared to the previous year all point towards a tough period for the company.
One key highlight from the results is the decline in inventories and the increase in accounts receivable. The decrease in inventories could indicate lower expected demand for the company's products, while the rise in accounts receivable could suggest an increase in sales but delayed payments. These factors can have implications for the company's future performance and growth prospects.

Upexi Inc

Upexi Inc Faces Unexpected Revenue Contraction, Amidst Second Quarter of 2024 Earnings Season

Upexi Inc, a leading player in the legal cannabis sector, has recently posted disappointing financial results for the most recent fiscal period. Despite these challenges, there are signs of potential growth and improvement on the horizon.
While the company reported a loss per share of $-0.12, a decline from the previous year, it is important to note that the legal cannabis sector as a whole has seen a 32.13% increase in revenue compared to the same period a year before. This indicates that there is still strong demand and opportunity in the industry, and Upexi Inc is well positioned to capitalize on this growth.






 

Tauriga Sciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com